Nivolumab in Patients With IDH-Mutant Gliomas With and Without Hypermutator Phenotype

PHASE2Active, not recruitingINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

March 27, 2019

Primary Completion Date

November 5, 2024

Study Completion Date

November 30, 2026

Conditions

GliomaGlioblastomaHigh Grage GliomaLow Grade GliomaMalignant Glioma

Interventions

DRUG

Nivolumab

IV Nivolumab

Trial Locations (1)

National Institutes of Health Clinical Center, Bethesda

All Listed Sponsors

lead

National Cancer Institute (NCI)

NIH

NCT03718767 - Nivolumab in Patients With IDH-Mutant Gliomas With and Without Hypermutator Phenotype | Biotech Hunter | Biotech Hunter